BioSpace News Archive

Orthofix Medical Inc. today announced the 510k clearance and full commercial launch of OsteoCove ™ , an advanced bioactive synthetic graft. Available in both a putty and strip configuration, OsteoCove was carefully formulated to provide superior bone-forming capabilities with best-in-class handling characteristics for a wide range of spine and orthopedic procedural applications.

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced multiple abstracts to be presented at IDWeek 2023 in Boston, Massachusetts (October 11-15, 2023).

Moderna, Inc. (Nasdaq:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 2, 2023 to report its third quarter 2023 financial results, and provide a corporate update.

Venus Concept Inc. today announced the promotion of Dr. Hemanth Varghese to the newly created role of President and Chief Operating Officer (COO), reporting to Chief Executive Officer, Rajiv De Silva, effective October 16, 2023.

Theratechnologies Inc. today announced dosing of the first participant in Part 3 of its Phase 1 clinical trial of sudocetaxel zendusortide in patients with advanced ovarian cancer.

Leading supply chain visibility provider FourKites today announced that Teva, a global leader in generic and innovative medicines, has achieved a 0.005% incident rate by leveraging FourKites’ global carrier visibility solution, NIC-Place.

FORE Biotherapeutics today announced the acceptance of an abstract on new nonclinical data related to plixorafenib (FORE8394), the company’s novel, investigational, small-molecule, next-generation, orally available selective inhibitor of BRAF alterations at the 2023 AACR-NCI-EORTC International Conference, taking place October 11-14, 2023, in Boston and virtually.

ProPhase Labs, Inc. today announced it will be participating in The ThinkEquity Conference, which will take place on October 19, 2023 at The Mandarin Oriental Hotel in New York.

Longeveron Inc. today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,424,243 of its shares of Class A common stock.

Akeso, Inc. (9926.HK) (“Akeso”) announced that the results of the multicenter, open-label Phase Ib/II clinical trial (COMPASSION-03/AK104-201) for cadonilimab (PD-1/CTLA-4 bispecific antibody), the globally first bispecific IO drug used to treat advanced solid tumors, have been published in the October 2 issue of The Lancet Oncology.